Education
About Us
Working with TipRanks
Follow Us
PetVivo Holdings (PETV)
OTHER OTC:PETV
Earnings Data
Report Date
Jun 25, 2026After Close (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
―Last Year’s EPS
-0.08Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Q3 2026
Earnings Call Date:Feb 17, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented a strongly positive strategic and operational narrative: management secured transformative partnerships (exclusive AI licensing, major distributor and channel agreements), advanced R&D and international commercialization (Health Canada recognition, U.K. and Mexico distribution), and materially reduced liabilities (≈81% decline). These developments position the company for a recurring, high-margin SaaS revenue stream (PetVivo AI) that could complement device and biologic sales. Near-term financials remain challenging — modest revenue decline (−2% YoY for nine months), lower gross margins from product mix, ongoing operating losses (net loss $7.5M) and cash burn ($5.3M) leave liquidity and timing risks. Overall, the strategic progress and balance sheet improvements outweigh the current financial headwinds, suggesting a Positive sentiment with execution and monetization of AI and commercialization plans as key drivers to watch.Company Guidance
Strategic AI Partnership and New SaaS Platform Launch
Signed an exclusive 10-year white-label license with Digital Landia for AgenticPet AI and launched PetVivo AI (B2B SaaS). Beta testing reported 50%–90% reduction in veterinary customer acquisition costs (from typical $80–$400 down to <$43 per target) and the platform claims high recurring revenue potential with 80%–90% gross margins and low CapEx.
Rapid Early Adoption of AgenticPet B2C Beta
Digital Landia's public B2C AgenticPet beta onboarded 1,000 active users in less than 72 hours, validating strong consumer demand and strengthening B2B PetVivo AI value proposition.
Key Distribution and Channel Partnerships
Entered significant commercial partnerships: Veterinary Growth Partners (VGP) committed to actively promote Spryng and PrecisePRP to its >7,300 clinic members; Nupsala Group began U.K. distribution (initial order shipped); Eq Especialidades signed for Mexico distribution—opening major international markets.
Regulatory Milestone — Canada Recognition
Health Canada acknowledged Spryng with OsteoCushion technology as a veterinary medical device, enabling planned commercial launch in Canada (targeted early Q3 calendar 2026) and opening a sizable international market opportunity.
Pipeline and R&D Progress
Progressed multi-stage R&D with PiezoBioMembrane: Stage A/B completed (material compatibility, piezoelectric activity, and scalable mass production with preliminary safety in animals); Stage C expected to begin in Q2 2026 to demonstrate definitive animal safety/efficacy and enable potential human FDA pathway thereafter. Canine elbow pilot study data collection completed and being prepared for white paper submission.
Product Commercialization Momentum — PrecisePRP
Commercial launch of PrecisePRP (allogenic PRP) underway under exclusive license with VetStem; received favorable veterinarian feedback on ease of use and are actively promoting at major industry conferences to drive adoption.
Significant Reduction in Total Liabilities
Total liabilities decreased to $1.0 million at Dec 31 (down from $5.1 million on Mar 31), representing an ~81% reduction over the nine-month period, primarily from convertible note conversions and extinguishment of derivative liabilities.
Stable Near-Term Revenue and Improved Working Capital Positioning
Nine-month revenues of $887,000 decreased only 2% year-over-year despite product mix shift; current assets of $1.4 million, current liabilities of $980,000 and working capital of $395,000. Subsequent to period end, $477,500 was raised via warrant exercises and equity sales.
PETV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PETV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 17, 2026 | $0.67 | $0.70 | +3.88% |
Nov 14, 2025 | $1.33 | $1.20 | -9.77% |
Aug 14, 2025 | $0.78 | $0.81 | +3.85% |
Jun 30, 2025 | $0.80 | $0.78 | -2.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does PetVivo Holdings (PETV) report earnings?
PetVivo Holdings (PETV) is schdueled to report earning on Jun 25, 2026, After Close (Confirmed).
What is PetVivo Holdings (PETV) earnings time?
PetVivo Holdings (PETV) earnings time is at Jun 25, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PETV EPS forecast?
Currently, no data Available